Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP

被引:61
作者
Kobayashi, Yoshimitsu [1 ]
Komatsu, Yoshito [2 ]
Yuki, Satoshi [1 ]
Fukushima, Hiraku [2 ]
Sasaki, Takahide [1 ]
Iwanaga, Ichiro [3 ]
Uebayashi, Minoru [3 ]
Okuda, Hiroyuki [4 ]
Kusumi, Takaya [5 ]
Miyagishima, Takuto [6 ]
Sogabe, Susumu [7 ]
Tateyama, Miki [8 ]
Hatanaka, Kazuteru [9 ]
Tsuji, Yasushi [10 ]
Nakamura, Michio [11 ]
Konno, Jun [12 ]
Yamamoto, Fumiyasu [13 ]
Onodera, Manabu [14 ]
Iwai, Kazuhiro [15 ]
Sakata, Yuh [16 ]
Abe, Riichiro [17 ]
Oba, Koji [18 ]
Sakamoto, Naoya [1 ]
机构
[1] Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido, Japan
[2] Hokkaido Univ Hosp, Dept Canc Ctr, Sapporo, Hokkaido 060, Japan
[3] Japanese Red Cross Kitami Hosp, Dept Gastroenterol, Kitami, Hokkaido, Japan
[4] Keiyukai Sapporo Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan
[5] Keiyukai Sapporo Hosp, Dept Surg, Sapporo, Hokkaido, Japan
[6] Kushiro Rosai Hosp, Dept Internal Med, Kushiro, Hokkaido, Japan
[7] Kushiro Rosai Hosp, Dept Med Oncol, Kushiro, Hokkaido, Japan
[8] Tomakomai Nisshou Hosp, Dept Internal Med, Tomakomai, Japan
[9] Hakodate Municipal Hosp, Dept Gastroenterol, Hakodate, Hokkaido, Japan
[10] Tonan Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan
[11] Sapporo City Gen Hosp, Dept Gastroenterol, Sapporo, Hokkaido, Japan
[12] Hakodate Cent Gen Hosp, Dept Internal Med, Hakodate, Hokkaido, Japan
[13] Tomakomai City Hosp, Dept Gastroenterol, Tomakomai, Japan
[14] Abashiri Kosei Gen Hosp, Dept Internal Med & Gastroenterol, Abashiri, Japan
[15] Oji Gen Hosp, Dept Surg, Tomakomai, Japan
[16] Misawa City Hosp, Misawa, Japan
[17] Hokkaido Univ, Grad Sch Med, Dept Dermatol, Sapporo, Hokkaido, Japan
[18] Hokkaido Univ Hosp, Translat Res & Clin Trial Ctr, Sapporo, Hokkaido 060, Japan
关键词
colorectal cancer; Japanese; panitumumab; pre-emptive; skin toxicities; GROWTH-FACTOR RECEPTOR; PHASE-III TRIAL; MONOCLONAL-ANTIBODY; OPEN-LABEL; MONOTHERAPY; FLUOROURACIL; CHEMOTHERAPY; LEUCOVORIN; MECHANISMS; IRINOTECAN;
D O I
10.2217/fon.14.251
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: We planned a randomized, open-label trial to evaluate differences between pre-emptive and reactive skin treatment for panitumumab (Pmab)-associated skin toxicities in Japanese patients with metastatic colorectal cancer. Patients & methods: Patients receiving third-line Pmab-containing regimens were randomized to pre-emptive or reactive treatment. The primary end point was the cumulative incidence of grade 2 skin toxicities during 6 weeks. Retrospectively, a dermatologist reviewed skin toxicities, in a blinded manner. Results: A total of 95 patients were enrolled (pre-emptive: 47, reactive: 48). The primary end point was achieved (21.3 and 62.5% [risk ratio: 0.34; p < 0.001], for pre-emptive and reactive treatment, respectively). A similar trend was observed in central review. Conclusion: Pre-emptive skin treatment could reduce the severity of Pmab-associated skin toxicities in Japanese metastatic colorectal cancer patients.
引用
收藏
页码:617 / 627
页数:11
相关论文
共 29 条
[1]   Epidermal growth factor receptor inhibitor-related skin toxicity: Mechanisms, treatment, and its potential role as a predictive marker [J].
Bianchini, Diletta ;
Jayanth, Akali ;
Chua, Yu Jo ;
Cunningham, David .
CLINICAL COLORECTAL CANCER, 2008, 7 (01) :33-43
[2]   Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: Survey results [J].
Boone, Susan L. ;
Rademaker, Alfred ;
Liu, Dachao ;
Pfeiffer, Carmen ;
Mauro, David J. ;
Lacouture, Mario E. .
ONCOLOGY, 2007, 72 (3-4) :152-159
[3]   The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer [J].
Bouche, Olivier ;
Beretta, Giordano Domenico ;
Garcia Alfonso, Pilar ;
Geissler, Michael .
CANCER TREATMENT REVIEWS, 2010, 36 :S1-S10
[4]   Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].
Cunningham, D ;
Humblet, Y ;
Siena, S ;
Khayat, D ;
Bleiberg, H ;
Santoro, A ;
Bets, D ;
Mueser, M ;
Harstrick, A ;
Verslype, C ;
Chau, I ;
Van Cutsem, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345
[5]   Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study [J].
Douillard, Jean-Yves ;
Siena, Salvatore ;
Cassidy, James ;
Tabernero, Josep ;
Burkes, Ronald ;
Barugel, Mario ;
Humblet, Yves ;
Bodoky, Gyoergy ;
Cunningham, David ;
Jassem, Jacek ;
Rivera, Fernando ;
Kocakova, Ilona ;
Ruff, Paul ;
Blasinska-Morawiec, Maria ;
Smakal, Martin ;
Canon, Jean-Luc ;
Rother, Mark ;
Oliner, Kelly S. ;
Wolf, Michael ;
Gansert, Jennifer .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (31) :4697-4705
[6]   EGFR inhibitor-associated acneiform folliculitis - Assessment and management [J].
Duvic, Madeleine .
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2008, 9 (05) :285-294
[7]  
Fakih M, 2010, CURR ONCOL, V17, pS18
[8]   DERMATOLOGY LIFE QUALITY INDEX (DLQI) - A SIMPLE PRACTICAL MEASURE FOR ROUTINE CLINICAL USE [J].
FINLAY, AY ;
KHAN, GK .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1994, 19 (03) :210-216
[9]   Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody [J].
Foon, KA ;
Yang, XD ;
Weiner, LM ;
Belldegrun, AS ;
Figlin, RA ;
Crawford, J ;
Rowinsky, EK ;
Dutcher, JP ;
Vogelzang, NJ ;
Gollub, J ;
Thompson, JA ;
Schwartz, G ;
Bukowski, RM ;
Roskos, LK ;
Schwab, GM .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (03) :984-990
[10]   Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147 [J].
Jatoi, Aminah ;
Green, Erin M. ;
Rowland, Kendrith M., Jr. ;
Sargent, Daniel J. ;
Alberts, Steven R. .
ONCOLOGY, 2009, 77 (02) :120-123